Lördag 21 December | 18:08:33 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-06 12:00 Kvartalsrapport 2025-Q3
2025-08-21 12:00 Kvartalsrapport 2025-Q2
2025-05-01 12:00 Kvartalsrapport 2025-Q1
2025-04-24 N/A Årsstämma
2025-03-20 N/A Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-02 - Kvartalsrapport 2024-Q1
2024-04-26 - X-dag ordinarie utdelning VIRO 0.00 DKK
2024-04-25 - Årsstämma
2024-03-21 - Bokslutskommuniké 2023
2023-11-24 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-04 - Kvartalsrapport 2023-Q1
2023-04-28 - X-dag ordinarie utdelning VIRO 0.00 DKK
2023-03-23 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-04 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning VIRO 0.00 DKK
2022-04-28 - Årsstämma
2022-03-23 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-04-28 - X-dag ordinarie utdelning VIRO 0.00 DKK
2021-04-27 - Årsstämma
2021-03-24 - Bokslutskommuniké 2020
2020-10-27 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-06-19 - X-dag ordinarie utdelning VIRO 0.00 DKK
2020-06-18 - Årsstämma
2020-04-30 - Kvartalsrapport 2020-Q1
2020-03-25 - Bokslutskommuniké 2019
2019-10-28 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-04-29 - Kvartalsrapport 2019-Q1
2019-04-26 - X-dag ordinarie utdelning VIRO 0.00 DKK
2019-04-25 - Årsstämma

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriMedicinteknik
Virogates är verksamt inom medicinteknik. Idag innehas affärsverksamhet inom forskning och utveckling av biomarkörer och diagnostiska instrument för sjukvårdsindustrin. Produkterna säljs under olika varumärken och används vid identifiering, analys och vidarebehandling av sjukdomar, främst hjärt- och kärlsjukdomar, cancer och neurologiska sjukdomar. Bolaget etablerades 2001 och har sitt huvudkontor i Birkerød.
2024-12-19 18:08:00

Company Announcement no. 13/2024 (December 19, 2024)

BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring the level of inflammation in individuals in health clinics and hospitals, today publishes the financial calendar for 2025 with the following key dates:

20 March 2025Annual Report 2024
3 April 2025Deadline for submission of business to be transacted at the 2025 Annual General Meeting
24 April 2025Annual General Meeting
1 May 2025Interim Report Q1 2025
21 August 2025Interim Report H1 2025
6 November 2025Interim Report Q1-Q3 2025

The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.

ViroGates encourages all shareholders to sign up to receive relevant shareholder information at its shareholder portal
(https://www.virogates.com/virogates-shareholder-portal).

Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 3rd April 2025 via email to jk@virogates.com or jbj@virogates.com.

For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se

About ViroGates
ViroGates A/S is an international medical technology company that develops blood tests to measure inflammation in individuals in health clinics and improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.